Managing tuberculosis in patients with diabetes mellitus: why we care and what we know

References

• Dye C, Watt CJ, Bleed DM, Hosseini SM, Raviglione MC. Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA 293(22), 2767–2775 (2005).
   PubMed Web of Science ®Google Scholar
• WHO. Global Tuberculosis Control: WHOReport 2010. WHO, Geneva, Switzerland (2010).
   Google Scholar
• Lönnroth K, Jaramillo E, Williams BG, Dye C, Raviglione M. Drivers of tuberculosis epidemics: the role of risk factors and social determinants. Soc. Sci. Med. 68(12), 2240–2246 (2009).
   PubMed Web of Science ®Google Scholar
• Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res. Clin. Pract. 94(3), 311–321 (2011).
   PubMed Web of Science ®Google Scholar
• Leung CC, Lam TH, Chan WM et al. Diabetic control and risk of tuberculosis: acohort study. Am. J. Epidemiol. 167(12), 1486–1494 (2008).
   PubMed Web of Science ®Google Scholar
• Baker MA, Lin HH, Chang HY, Murray MB. The risk of tuberculosis disease among persons with diabetes mellitus: a prospective cohort study. Clin. Infect. Dis. 54(6), 818–825 (2012).
   PubMed Web of Science ®Google Scholar
• Baker MA, Harries AD, Jeon CY et al. Theimpact of diabetes on tuberculosis treatment outcomes: a systematic review. BMC Med. 9, 81 (2011).
   PubMed Web of Science ®Google Scholar
• Martens GW, Arikan MC, Lee J, Ren F, Greiner D, Kornfeld H. Tuberculosis susceptibility of diabetic mice. Am. J. Respir. Cell Mol. Biol. 37(5), 518–524 (2007).
   PubMed Web of Science ®Google Scholar
• Chang FY, Shaio MF. Decreased cell-mediated immunity in patients with non-insulin-dependent diabetes mellitus. Diabetes Res. Clin. Pract. 28(2), 137–146 (1995).
   PubMed Web of Science ®Google Scholar
• Rayfield EJ, Ault MJ, Keusch GT, Brothers MJ, Nechemias C, Smith H. Infection and diabetes: the case for glucose control. Am.J. Med. 72(3), 439–450 (1982).
   PubMed Web of Science ®Google Scholar
• Saiki O, Negoro S, Tsuyuguchi I, Yamamura Y. Depressed immunological defence mechanisms in mice with experimentally induced diabetes. Infect.Immun. 28(1), 127–131 (1980).
   PubMedGoogle Scholar
• Sugawara I, Mizuno S. Higher susceptibility of Type 1 diabetic rats to Mycobacterium tuberculosis infection. Tohoku J. Exp. Med. 216(4), 363–370 (2008).
   PubMedGoogle Scholar
• Sugawara I, Yamada H, Mizuno S. Pulmonary tuberculosis in spontaneously diabetic goto kakizaki rats. Tohoku J. Exp. Med. 204(2), 135–145 (2004).
   PubMedGoogle Scholar
• Vallerskog T, Martens GW, Kornfeld H. Diabetic mice display a delayed adaptive immune response to Mycobacterium tuberculosis. J. Immunol. 184(11), 6275–6282 (2010).
   PubMedGoogle Scholar
• Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: asystematic review of 13 observational studies. PLoS Med. 5(7), e152 (2008).
   PubMed Web of Science ®Google Scholar
• Baker MA, Lin HH, Chang HY, Murray MB. The risk of tuberculosis disease among persons with diabetes mellitus: aprospective cohort study. Clin. Infect. Dis. 54(6), 818–825 (2012).
   PubMed Web of Science ®Google Scholar
• Jeon CY, Harries AD, Baker MA et al. Bi-directional screening for tuberculosis and diabetes: a systematic review. Trop. Med. Int. Health 15(11), 1300–1314 (2010).
   PubMed Web of Science ®Google Scholar
• Alisjahbana B, van Crevel R, Sahiratmadja E et al. Diabetes mellitus is strongly associated with tuberculosis in Indonesia. Int. J. Tuberc. Lung Dis. 10(6), 696–700 (2006).
   PubMed Web of Science ®Google Scholar
• Golsha R, Rezaei SR, Shafiee A, Najafi L, Dashti M, Roshandel G. Pulmonary tuberculosis and some underlying conditions in Golestan Province of Iran, during 2001–2005. J. Clin. Diag. Res. 3(1), 1302–1306 (2009).
   Google Scholar
• Ponce-De-Leon A, Garcia-Garcia Md Mde L, Garcia-Sancho MC et al. Tuberculosis and diabetes in southern Mexico. Diabetes Care 27(7), 1584–1590 (2004).
   PubMed Web of Science ®Google Scholar
• Restrepo BI, Camerlin AJ, Rahbar MH et al. Cross-sectional assessment reveals high diabetes prevalence among newly-diagnosed tuberculosis cases. Bull. World Health Organ. 89(5), 352–359 (2011).
   PubMed Web of Science ®Google Scholar
• Gupta S, Shenoy VP, Bairy I, Srinivasa H, Mukhopadhyay C. Diabetes mellitus and HIV as co-morbidities in tuberculosis patients of rural south India. J. Infect. Public Health 4(3), 140–144 (2011).
   PubMedGoogle Scholar
• Wang CS, Yang CJ, Chen HC et al. Impact of Type 2 diabetes on manifestations and treatment outcome of pulmonary tuberculosis. Epidemiol. Infect. 137(2), 203–210 (2009).
   PubMed Web of Science ®Google Scholar
• Chiang CY, Lee JJ, Yu MC, Enarson DA, Lin TP, Luh KT. Tuberculosis outcomes in Taipei: factors associated with treatment interruption for 2 months and death. Int. J. Tuberc. Lung Dis. 13(1), 105–111 (2009).
   PubMed Web of Science ®Google Scholar
• Rieder HL. Sputum smear conversion during directly observed treatment for tuberculosis. Tuber. Lung Dis. 77(2), 124–129 (1996).
   PubMedGoogle Scholar
• Ramarokoto H, Randriamiharisoa H, Rakotoarisaonina A et al. Bacteriological follow-up of tuberculosis treatment: acomparative study of smear microscopy and culture results at the second month of treatment. Int. J. Tuberc. Lung Dis. 6(10), 909–912 (2002).
   PubMedGoogle Scholar
• Nijland HM, Ruslami R, Stalenhoef JE et al. Exposure to rifampicin is strongly reduced in patients with tuberculosis and Type 2 diabetes. Clin. Infect. Dis. 43(7), 848–854 (2006).
   PubMed Web of Science ®Google Scholar
• Ruslami R, Nijland HM, Adhiarta IG et al. Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with Type 2 diabetes. Antimicrob. Agents Chemother. 54(3), 1068–1074 (2010).
   PubMed Web of Science ®Google Scholar
• Launay-Vacher V, Izzedine H, Deray G. Pharmacokinetic considerations in the treatment of tuberculosis in patients with renal failure. Clin. Pharmacokinet. 44(3), 221–235 (2005).
   PubMedGoogle Scholar
• Niemi M, Backman JT, Neuvonen PJ. Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone. Clin. Pharmacol. Ther. 76(3), 239–249 (2004).
   PubMed Web of Science ®Google Scholar
• Niemi M, Backman JT, Neuvonen M, Neuvonen PJ, Kivistö KT. Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. Clin. Pharmacol. Ther. 69(6), 400–406 (2001).
   PubMed Web of Science ®Google Scholar
• Chang JT, Dou HY, Yen CL et al. Effect of Type 2 diabetes mellitus on the clinical severity and treatment outcome in patients with pulmonary tuberculosis: a potential role in the emergence of multidrug-resistance. J. Formos. Med. Assoc. 110(6), 372–381 (2011).
   PubMed Web of Science ®Google Scholar
• Pfaffenberg R, Jahler H. Isoniazid & recurrence of tuberculosis in diabetics. Z.Tuberk. 111(3–4), 167–173 (1958).
   PubMedGoogle Scholar
• WHO, International Union Against Tuberculosis and Lung Disease. Collaborative Framework for Care and Controlof Tuberculosis and Diabetes. WHO, Geneva, Switzerland (2011).
   Google Scholar
• Blumberg HM, Burman WJ, Chaisson RE et al.; American Thoracic Society, Centers for Disease Control and Prevention and the Infectious Diseases Society. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 167(4), 603–662 (2003).
   PubMed Web of Science ®Google Scholar
• WHO. Stop TB Dept. Treatment of Tuberculosis: Guidelines. WHO, Geneva, Switzerland (2010).
   Google Scholar
• Pacific Island TB Controllers Association (Pitca). USAPI standards for the management of tuberculosis and diabetes. USAPI Standards for the Management of Tuberculosis and Diabetes 2012. 19 March 2011.
   Google Scholar
• Lesnichii AV, Karpina LZ. Experience with the chemoprophylaxis of pulmonary tuberculosis in diabetes mellitus patients. Probl. Tuberk. 47(12), 1–3 (1969).
   PubMedGoogle Scholar
• American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: controlling tuberculosis in the United States. Am. J. Respir. Crit. Care Med. 172(9), 1169–1227 (2005).
   PubMed Web of Science ®Google Scholar
• Restrepo BI. Convergence of the tuberculosis and diabetes epidemics: renewal of old acquaintances. Clin. Infect. Dis. 45(4), 436–438 (2007).
   PubMedGoogle Scholar
• Allain TJ, van Oosterhout JJ, Douglas GP et al. Applying lessons learnt from the ‘DOTS’ Tuberculosis Model to monitoring and evaluating persons with diabetes mellitus in Blantyre, Malawi. Trop. Med. Int. Health 16(9), 1077–1084 (2011).
   PubMedGoogle Scholar
• World Health Organization Western Pacific Region. Federated States of Micronesia (Pohnpei) NCD Risk Factors STEPS Report. Federated States of Micronesia (Pohnpei) NCD Risk Factors STEPS Report (2008).
   Google Scholar
• Harries AD, Lin Y, Satyanarayana S et al. The looming epidemic of diabetes-associated tuberculosis: learning lessons from HIV-associated tuberculosis. Int. J. Tuberc. Lung Dis. 15(11), 1436–1444, i (2011).
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes – 2012. DiabetesCare 35(Suppl. 1), S11–S63 (2012).
   Google Scholar
• Gnanasan S, Ting KN, Wong KT, Mohd Ali S, Muttalif AR, Anderson C. Convergence of tuberculosis and diabetes mellitus: time to individualise pharmaceutical care. Int. J. Clin. Pharm. 33(1), 44–52 (2011).
   PubMedGoogle Scholar